RQS
KALV

Ramsey Quantitative Systems’s KalVista Pharmaceuticals KALV Stock Holding History

Ramsey Quantitative Systems’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,789
Closed -$35K – 134
2018
Q4 		$35K Buy
+1,789
New +$36K 0.04% 302

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Ramsey Quantitative Systems's KALV Position: Q1 2019 in Review

Ramsey Quantitative Systems sold out of KalVista Pharmaceuticals (KALV) in Q1 2019, closing a stake of 1,789 shares — an estimated $35K sold.

Ramsey Quantitative Systems first reported a position in KALV in Q4 2018 and held it in 1 quarter. The position peaked at $35K in Q4 2018. 68 funds tracked by Wall St. Rank hold KALV as of Q1 2019.

  • Ramsey Quantitative Systems reported no remaining KalVista Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Ramsey Quantitative Systems sold 1,789 KalVista Pharmaceuticals shares in Q1 2019, an estimated $35K.
  • Ramsey Quantitative Systems first reported a position in KalVista Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Ramsey Quantitative Systems's KalVista Pharmaceuticals position peaked at $35K in Q4 2018.
  • 68 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2019.

Based on Ramsey Quantitative Systems's 13F filing for Q1 2019, filed 23 Apr 2019.